Celiac Disease (CD) Epidemiology Forecast 2025-2034

Celiac disease is an inherited autoimmune disorder characterized by an immune reaction to eating gluten (a protein present in barley, wheat, and rye). The condition is estimated to impact 1% of the populations of North America and Europe, with around 97% of the patients carrying a recognizable gene mutation (HLA-DQ2 or HLA-DQ8).

Celiac Disease (CD) Epidemiology Forecast Report Coverage

The “Celiac Disease (CD) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of celiac disease (CD). It projects the future incidence and prevalence rates of celiac disease (CD) across various populations. The study covers age, gender, and type as major determinants of the celiac disease (CD)-affected population. The report highlights patterns in the prevalence of celiac disease (CD) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of celiac disease (CD) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Celiac Disease (CD) Disease Overview

Celiac disease (celiac sprue) is more serious than a normal food intolerance as it triggers the immune system to attack gluten in the small intestine. The antibodies produced in reaction to the gluten in the digestive system damage the lining of the small intestine, which can impair its ability to absorb nutrients from the food. Celiac disease can develop at any age, with healthcare providers observing it commonly during early childhood and mid-life (between 40 and 60 years).

Celiac Disease (CD): Treatment Overview

Celiac disease patients are advised to stop eating gluten and maintain a strict gluten-free diet in order to avoid any immune reaction. Additional treatment includes nutritional supplements to address any serious deficiencies, corticosteroids for tackling severe inflammation, certain drugs for treating dermatitis herpetiformis, and continuous follow-up care. It is also observed that the majority of the patients notice considerable relief from their symptoms almost immediately after starting a gluten-free diet.

Epidemiology

The celiac disease (CD) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for celiac disease (CD) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for celiac disease (CD) and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Approximately 1% of the global population is estimated to be affected by celiac disease, with the prevalence higher in people with certain chromosomal disorders.
• An individual with a first-degree relative (such as a parent or child) affected by celiac disease has a 10% chance of developing the autoimmune condition.
• Celiac disease is more prevalent in people assigned female at birth, with a ratio between women and men reported to be around 2:1.
• According to the Celiac Disease Foundation, the incidence of celiac disease among children and adults was estimated to be 21.3 and 12.9 per 100,000 person-years, respectively.

Country-wise Celiac Disease (CD) Epidemiology

The celiac disease (CD) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of celiac disease (CD) varies between countries owing to differences in in genetic predisposition (such as the prevalence of HLA-DQ2 and HLA-DQ8 genes), dietary habits (particularly wheat and gluten consumption), diagnostic awareness, and healthcare infrastructure, among others. It is estimated that around 2 million individuals are affected by celiac disease in the United States.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of celiac disease (CD) based on several factors.
• Celiac Disease (CD) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of celiac disease (CD) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of celiac disease (CD) epidemiology in the 8 major markets?
• What will be the total number of patients with celiac disease (CD) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of celiac disease (CD) in the 8 major markets in the historical period?
• Which country will have the highest number of celiac disease (CD) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of celiac disease (CD) during the forecast period of 2025-2034?
• What are the currently available treatments for celiac disease (CD)?
• What are the disease risks, signs, symptoms, and unmet needs of celiac disease (CD)?

This product will be delivered within 3-5 business days.